RBC Capital analyst Simos Simeonidis maintained an Outperform rating and lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA Hot Comments Momentum Movers Short Sales Trader Talk

Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death October 16, 2015 1:28 PM Zafgen (ZFGN) PT Cut to $48 at FBR Capital on Patient DeathOctober 15, 2015 6:39 AM RBC Sees 33% of Zafgen (ZFGN) Death Happening in Placebo Arm; Reiterates 'Outperform' RatingOctober 14, 2015 2:48 PM Leerink Partners Comments on Zafgen (ZFGN) Following Patient DeathOctober 14, 2015 2:26 PM Zafgen (ZFGN) Stock Expected to Languish Until More is Known - CowenOctober 14, 2015 2:20 PM Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - BloombergOctober 14, 2015 1:18 PM Who Traded Zafgen (ZFGN) on Illegal Insider Information?October 14, 2015 12:54 PM Zafgen (ZFGN) Learns of Death in Beloranib Phase 3October 14, 2015 12:27 PM Zafgen (ZFGN) Issues Statement; FDA Initiates Discussion Following Phase 3 bestPWS DeathOctober 14, 2015 12:01 PM Zafgen Issues StatementOctober 14, 2015 11:59 AM